Who we are: BCBA connects academic science trainees and recent graduates to the Bay Area’s biotech industry through hands-on consulting and due diligence projects. We are a volunteer organization composed of PhD students, post-docs, medical trainees, and young professionals looking to gain professional development skills for jobs in biotech companies, consulting, and venture capital. Over […]
Community News
Strategize the adoption of a novel in vivo screening platform by pharmaceutical companies
February 1, 2022
Market opportunity assessment for a novel electroporation technology
January 26, 2022
Who we are: BCBA connects academic science trainees and recent graduates to the Bay Area’s biotech industry through hands-on consulting and due diligence projects. We are a volunteer organization composed of PhD students, post-docs, medical trainees, and young professionals looking to gain professional development skills for jobs in biotech companies, consulting, and venture capital. Over […]
Due diligence to guide venture capital investment
December 8, 2021
The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]
Indication prioritization for a therapeutics company targeting aging diseases
December 8, 2021
As advances in medicine and technology have enabled societies to enjoy longer lifespans, increasing numbers of people will live to experience the negative effects age-associated diseases. An early-stage therapeutics company has engaged BCBA to identify appropriate molecular targets to combat age-associated diseases using high-throughput, high-dimensional approaches. Specifically, the BCBA team will use primary and secondary […]
Market opportunity assessment for a molecular structure determination platform company
October 21, 2021
An early-stage contract research organization (CRO) is providing high-throughput molecular structure determination services using a cutting-edge platform, enabling them to determine structures cheaper and more quickly than many competitors. The company believes that these advantages will enable them to capture a significant proportion of the molecular structure determination market, and that a large market opportunity […]
GPCR targets for an antibody therapeutics company
September 11, 2021
An early-stage biotechnology company with expertise in antibody therapeutics development is engaging BCBA to explore the GPCR-targeted therapeutics market. To that end, the BCBA project team will 1) conduct a comprehensive market landscape analysis of the GPCR therapeutic market to understand the market conditions and requirements for the development of compelling Proof-of-Concept (POC) programs in […]
Due diligence to guide venture capital investment
August 27, 2021
The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]
Strategic planning to increase awareness and adoption of Far-UVC light technology
June 12, 2021
An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]
Optimization of a direct-to-consumer test for the assessment of chronic inflammation
March 26, 2021
A direct-to-consumer (DTC) diagnostics company is developing a blood test panel for the assessment of chronic inflammation. Using a cutting-edge AI-based platform, the company is optimizing a panel that can provide their customers with deep insights on their inflammatory status with only a few drops of blood. Given the massive increase in DTC and telemedicine […]
Application prioritization for a next-generation antibody design and characterization platform
March 12, 2021
An early stage protein therapeutics company has developed a novel AI-driven platform for rapid, iterative antibody design and characterization and is in the process of prioritizing applications of their platform for a set of initial Proof of Concept (POC) programs. To that end, the BCBA project team will 1) evaluate the current research and framework […]